A compound under development by Albany Molecular Research, Inc. and Bristol-Myers Squibb will proceed into preclinical development, triggering a $1.5 million payment to AMRI. This is the first milestone in the companies’ research collaboration to develop improved treatments for depression and diseases of the central nervous system (CNS). Under the 2005 licensing agreement, BMS received an exclusive license to develop and commercialize a series of biogenic amine reuptake inhibitors fro...